21 October 2026 · 3 min read · By Clinical Trials
Phases of Clinical Trials: Phase 1, 2, 3 and 4 Explained
A plain-language guide to clinical trial phases: what each phase investigates, who may participate and why a phase number does not guarantee safety or benefit.
Clinical trial phases describe stages of research, particularly for medicines and biological products. Each stage asks different questions about an intervention. Clinical trials phases are often described as Phase 1 through Phase 4, but some studies combine phases and some kinds of research do not have an applicable phase.
A phase number tells you something about the study’s purpose, not whether a treatment is right for you. The protocol, available evidence and your medical circumstances all matter.
Phase 1: initial safety and dose research
Phase 1 usually examines initial safety, tolerability, dose and how a medicine behaves in the body. Researchers may study how it is absorbed, distributed, metabolised and eliminated. These studies often involve relatively small groups.
Some Phase 1 trials recruit healthy volunteers, while others recruit people with the condition being studied. For example, many oncology trials involve patients rather than healthy participants. Do not assume that an early-phase trial is open to everyone or that it has no meaningful risks.
Phase 2: effectiveness and continued safety
Phase 2 investigates whether an intervention shows effectiveness for its intended use while continuing to assess safety. Researchers may compare doses or treatment schedules and examine outcomes in participants with the relevant condition.
Encouraging results are not the same as proof of benefit for every patient. Study size, comparison groups, measured outcomes and follow-up duration influence what can be concluded.
Phase 3: broader evidence for benefit and risk
Phase 3 generally involves larger groups and aims to provide more substantial evidence about effectiveness and safety. A study may compare an intervention with an existing treatment or another appropriate control. The choice of comparator depends on the research question and ethical considerations.
Phase 3 data can support a regulatory submission, but completing a Phase 3 study does not automatically mean that a medicine will be approved. Regulators evaluate the overall evidence and benefit–risk balance.
Phase 4: research after approval
Phase 4 studies take place after approval and can examine additional safety or effectiveness questions in use. Approval does not end research: uncommon effects, longer-term outcomes and use in different populations may need further investigation.
Phase 0, combined phases and studies with no phase
Early Phase 1, sometimes called Phase 0, can involve limited exploratory exposure before more extensive development. Some trials are labelled Phase 1/Phase 2 or Phase 2/Phase 3. Device, behavioural and other studies may show “Not Applicable” in the phase field; that does not mean they are not research studies.
Before joining, ask what the specific trial is designed to learn, what evidence already exists, and what follow-up is required. This overview is educational and does not replace advice from the study doctor or your own clinician.